Perimenopause, and the years nobody warns you about

Menopause is a single day — twelve months after the final period — and almost everything people mean by the word happens in the years before it.

What perimenopause is

The transition during which ovarian function becomes erratic before ceasing.

It commonly begins in the mid-forties and can begin considerably earlier, and it lasts on average around four years with a range that extends well beyond a decade.

The characteristic feature is variability rather than decline: oestradiol fluctuates, sometimes to levels higher than in earlier reproductive years, which is why symptoms come and go and why a single blood test is a poor diagnostic tool in this age group.

Guidelines in several countries state explicitly that perimenopause in a woman over forty-five is diagnosed on symptoms and cycle changes rather than on hormone measurement.

The symptoms beyond the familiar ones

Hot flushes and night sweats are the best known and are far from universal or exclusive.

Cycle changes: shorter, longer, heavier, lighter, skipped, unpredictable.

Sleep disruption, which frequently precedes everything else and is not always caused by night sweats.

Mood changes, including anxiety, irritability and low mood, with an elevated risk of depressive episodes during the transition that is documented in longitudinal studies.

Cognitive symptoms — word-finding difficulty, poor concentration, memory lapses — which are frightening, are generally transient, and are consistently reported.

Joint and muscle aches, which surprise people and are common.

Palpitations, headaches and migraines that change pattern.

Genitourinary symptoms: vaginal dryness, discomfort with sex, urinary frequency and recurrent urinary infections, which unlike most other symptoms do not resolve with time and tend to progress without treatment.

And changes in libido, which have hormonal, physical and contextual components simultaneously.

Why it gets missed

Because the symptoms are non-specific and arrive in a decade of life that is frequently full of other explanations — demanding work, adolescent children, ageing parents.

Because many people, including some clinicians, associate menopause with the end of periods and do not connect symptoms occurring while cycles continue.

And because women reporting these symptoms have historically been offered antidepressants for what is a hormonal transition, which several guidelines now explicitly caution against as a first-line response to low mood arising in perimenopause.

Hormone therapy

The area most distorted by a single study's early reporting.

The Women's Health Initiative results in the early 2000s were widely reported in a way that caused a collapse in prescribing, and subsequent reanalysis has substantially qualified the picture — particularly regarding the age at which therapy is started, the formulation used and the route of administration.

Current guidance in several countries holds that for most women under sixty, or within ten years of menopause, with troublesome symptoms, the benefits of hormone therapy outweigh the risks.

Transdermal oestrogen does not carry the venous thrombosis risk associated with oral preparations, which matters for many women.

Progestogen is required alongside oestrogen for anyone with a uterus, to protect the endometrium.

Breast cancer risk with combined therapy is real, is related to duration, and is of a magnitude comparable to several lifestyle factors — which is information for a personal decision rather than a reason for a blanket answer.

Vaginal oestrogen for genitourinary symptoms is a separate matter: it is minimally absorbed, is not the same as systemic therapy, and is appropriate for many women who cannot or choose not to take systemic hormones.

Non-hormonal options

Which matter for those who cannot or prefer not to use hormones.

Cognitive behavioural therapy has evidence for hot flushes and for sleep and mood in this context.

Certain non-hormonal medications reduce vasomotor symptoms, and newer agents targeting the relevant neural pathway have become available in some countries.

Vaginal moisturisers and lubricants address dryness, and are distinct from each other in purpose.

Weight, alcohol, smoking and exercise all influence symptom burden.

Supplements marketed for menopause have generally weak evidence and are not regulated as medicines, and some plant oestrogens have theoretical interactions worth discussing.

What else changes

The decline in oestrogen accelerates bone loss and alters cardiovascular risk profile, which makes this a sensible point to review blood pressure, lipids, weight-bearing exercise, calcium and vitamin D, and family history.

Contraception remains necessary until the accepted point after the final period, since erratic ovulation still occurs.

And any bleeding after menopause is established requires prompt medical assessment, without exception.

General information only, not medical advice. Guidance varies by country — discuss symptoms and treatment options with a qualified clinician who knows your history.